GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » EV-to-EBITDA

Microbix Biosystems (TSX:MBX) EV-to-EBITDA : 6.59 (As of Jun. 13, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Microbix Biosystems's enterprise value is C$41.94 Mil. Microbix Biosystems's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was C$6.37 Mil. Therefore, Microbix Biosystems's EV-to-EBITDA for today is 6.59.

The historical rank and industry rank for Microbix Biosystems's EV-to-EBITDA or its related term are showing as below:

TSX:MBX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -97.09   Med: 17.4   Max: 275.61
Current: 6.59

During the past 13 years, the highest EV-to-EBITDA of Microbix Biosystems was 275.61. The lowest was -97.09. And the median was 17.40.

TSX:MBX's EV-to-EBITDA is ranked better than
55.23% of 449 companies
in the Biotechnology industry
Industry Median: 9.36 vs TSX:MBX: 6.59

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-13), Microbix Biosystems's stock price is C$0.35. Microbix Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.030. Therefore, Microbix Biosystems's PE Ratio for today is 11.67.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Microbix Biosystems EV-to-EBITDA Historical Data

The historical data trend for Microbix Biosystems's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems EV-to-EBITDA Chart

Microbix Biosystems Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.97 -11.80 13.67 16.95 18.79

Microbix Biosystems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.94 -96.90 18.79 8.01 6.91

Competitive Comparison of Microbix Biosystems's EV-to-EBITDA

For the Biotechnology subindustry, Microbix Biosystems's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbix Biosystems's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's EV-to-EBITDA falls into.



Microbix Biosystems EV-to-EBITDA Calculation

Microbix Biosystems's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=41.938/6.366
=6.59

Microbix Biosystems's current Enterprise Value is C$41.94 Mil.
Microbix Biosystems's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$6.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbix Biosystems  (TSX:MBX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Microbix Biosystems's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.35/0.030
=11.67

Microbix Biosystems's share price for today is C$0.35.
Microbix Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.030.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Microbix Biosystems EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbix Biosystems (TSX:MBX) Business Description

Traded in Other Exchanges
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.
Executives
James Stuart Currie Senior Officer

Microbix Biosystems (TSX:MBX) Headlines

No Headlines